{
  "PMC": "5926383",
  "DOI": "10.1111/j.1349-7006.2000.tb00979.x",
  "PMID": "10835500",
  "PMCID": "PMC5926383",
  "title": "Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.",
  "year": 2000,
  "source_url": "https://europepmc.org/article/PMC/PMC5926383",
  "source": "MED",
  "abstract_text": "6-2-(Dimethylamino)ethylămino-3-hydroxy-7H-indeno2, 1-cquinolin-7-one dihydrochloride (TAS-103) is a novel anticancer agent that was developed to target both topoisomerase (Topo) I and Topo II. To elucidate its mechanism of action, we have established and characterized TAS-103-resistant cells, derived from mouse leukemia (P388), human colon cancer (DLD-1), and human lung adenocarcinoma (A549) cell lines, by exposure to stepwisely increasing concentrations of TAS-103 in the culture medium. P388 / TAS cells showed only cross-resistance to VP-16 and adriamycin (ADR). The Topo II activity in these cells was decreased to below one-fourth of that in the parental cells, while the Topo I activity remained unchanged. DLD / TAS cells appeared to be cross-resistant to VP-16, ADR, camptothecin (CPT), SN-38 and vincristine (VCR). The enzymatic activities of both Topo I and Topo II in these cells were decreased to one-fourth of that observed in the parental cells. Furthermore, the decreased activities were accompanied by lower expression at the mRNA and protein levels. A549 / TAS cells acquired cross-resistance to VP-16, ADR and VCR, though the Topo activities were virtually unchanged. In this cell line, the intracellular accumulation of TAS-103 was significantly decreased and the expression of multidrug resistance associated protein (MRP) was elevated when compared with the parental cells. The results indicate that the affected activities of Topo I and / or Topo II, and in some instances decreased accumulation of TAS-103, are associated with the development of resistance to TAS-103, although the main mechanism of resistance to TAS-103 varied among cell lines.",
  "full_text": "Jpn J Cancer Res Jpn. J. Cancer Res 10.1111/(ISSN)1349-7006a CAS Japanese Journal of Cancer Research : Gann 0910-5050 1876-4673 Blackwell Publishing Ltd Oxford, UK 5926383 10835500 10.1111/j.1349-7006.2000.tb00979.x CAE543 Article Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐ c ]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines Aoyagi Yoshimi 1 Kobunai Takashi 1 Utsugi Teruhiro 1 Wierzba Konstanty 1 Yamada Yuji 1 Taiho Pharmaceutical Co., Ltd., Hanno Research Center, 1‐27 Misugidai, Hanno, Saitama 357–8527 * To whom correspondence and reprints requests should be addressed.E‐mail: aoyagiyo@taiho.hanno.co.jp 5 2000 91 5 10.1111/cas.2000.91.issue-5 543 550 (Received December 25, 1999/Revised February 22, 2000/ Accepted February 29, 2000) 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐ c ]quinol in‐7‐one dihydrochloride (TAS‐103) is a novel anticancer agent that was developed to target both topoisomerase (Topo) I and Topo II. To elucidate its mechanism of action, we have established and characterized TAS‐103‐resistant cells, derived from mouse leukemia (P388), human colon cancer (DLD‐1), and human lung adenocarcinoma (A549) cell lines, by exposure to stepwisely increasing concentrations of TAS‐103 in the culture medium. P388/TAS cells showed only cross‐resistance to VP‐16 and adriamycin (ADR). The Topo II activity in these cells was decreased to below one‐fourth of that in the parental cells, while the Topo I activity remained unchanged. DLD/TAS cells appeared to be cross‐resistant to VP‐16, ADR, camptothecin (CPT), SN‐38 and vincristine (VCR). The enzymatic activities of both Topo I and Topo II in these cells were decreased to one‐fourth of that observed in the parental cells. Furthermore, the decreased activities were accompanied by lower expression at the mRNA and protein levels. A549/TAS cells acquired cross‐resistance to VP‐16, ADR and VCR, though the Topo activities were virtually unchanged. In this cell line, the intracellular accumulation of TAS‐103 was significantly decreased and the expression of multidrug resistance associated protein (MRP) was elevated when compared with the parental cells. The results indicate that the affected activities of Topo I and/or Topo II, and in some instances decreased accumulation of TAS‐103, are associated with the development of resistance to TAS‐103, although the main mechanism of resistance to TAS‐103 varied among cell lines. TAS‐103 Topoisomerases Resistance source-schema-version-number 2.0 cover-date May 2000 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015 REFERENCES 1 ) Chen , A.Y. and Liu , L. F. DNA topoisomerases: essential enzymes and lethal targets . Annu. Rev. Pharmacol. Toxicol. , 34 , 191 – 218 ( 1994 ). 8042851 2 ) Takano , H. , Kohno , K. , Matsuo , K. , Matsuda , T. and Kuwano , M. DNA topoisomerase‐targeting antitumor agent and drug resistance . Anticancer Drugs , 3 , 323 – 330 ( 1999 ). 3 ) Utsugi , T. , Aoyagi , K. , Asao , T. , Okazaki , S. , Aoyagi , Y. , Sano , M. , Wierzba , K. and Yamada , Y. Antitumor activity of a novel quinoline derivative, TAS‐103, with inhibitory effects on topoisomerases I and II . Jpn. J. Cancer Res. , 88 , 992 – 1002 ( 1997 ). 9414662 4 ) Aoyagi , Y. , Kobunai , T. , Utsugi , T. , Oh‐hara , T. and Yamada , Y. In vitro antitumor activity of TAS‐103, a novel quinoline derivative that targets topoisomerases I and II . Jpn. J. Cancer Res. , 90 , 578 – 588 ( 1999 ). 10391099 5 ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Isoe , T. and Tsuruo , T. Decreased expression of DNA topoisomerase I in camptothecin‐resistant tumor cell lines as determined by a monoclonal antibody . Cancer Res. , 50 , 6925 – 6930 ( 1990 ). 2170010 6 ) Matsuo , K. , Kohno , K. , Takano , H. , Sato , S. , Kiue , A. and Kuwano , M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide‐resistant human cancer KB cell lines . Cancer Res. , 50 , 5919 – 5924 ( 1990 ). 2168285 7 ) Long , B. H. , Wang , L. , Lorico , A. , Wang , R. C. C. , Brattain , M. G. and Casazza , A. M. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines . Cancer Res. , 51 , 5725 – 5284 ( 1991 ). 8 ) Kubota , N. , Nishio , K. , Takeda , Y. , Ohmori , T. , Funayama , Y. , Ogasawara , H. , Ohira , T. , Kunikake , H. , Terashima , Y. and Saijo , N. Characterization of an etoposide‐resistant human ovarian cancer cell line . Cancer Chemother. Pharmacol. , 34 , 183 – 190 ( 1994 ). 7911742 9 ) Tamura , H. , Kohchi , C. , Yamada , R. , Ikeda , T. , Koiwai , O. , Patterson , E. , Keene , D. J. , Okada , K. , Kjeidsen , E. , Nishikawa , K. and Andho , T. Molecular cloning of a cDNA of a camptothecin‐resistant human DNA topoisomerase I and identification of mutation sites . Nucleic Acids Res. , 19 , 69 – 75 ( 1991 ). 1849260 10 ) Kubota , N. , Kanzawa , F. , Nishio , K. , Takeda , Y. , Ohmori , T. , Fujiwara , Y. , Terashima , Y. and Saijo , N. Detection of topoisomerase I gene point mutation in CPT‐11 resistant lung cancer cell line . Biochem. Biophys. Res. Commun. , 188 , 571 – 577 ( 1992 ). 1332703 11 ) Bugg , B. Y. , Danks , M. K. , Beck , W. T. and Suttle , D. P. Expression of a mutant DNA topoisomerase II in CCRFCEM human leukemia cells selected for resistance to teniposide . Proc. Natl. Acad. Sci. USA , 88 , 7654 – 7658 ( 1991 ). 1652758 12 ) Saleem , A. , Ibrahin , N. , Patel , M. , Li , X. , Gupta , E. , Mendoza , J. , Pantazis , P. and Rubin , H. E. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning . Cancer Res. , 57 , 5100 – 5106 ( 1997 ). 9371509 13 ) Minato , K. , Kanazawa , F. , Nishio , K. , Nakagawa , K. , Fujiwara , Y. and Saijo , N. Characterization of an etoposide‐resistant human small‐cell lung cancer cell line . Cancer Chemother. Pharmacol. , 26 , 313 – 317 ( 1990 ). 1976450 14 ) Schneider , E. , Horton , J. K. , Yang , C. H. , Nakagawa , M. and Cowan , K. H. Multidrug resistance‐associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide . Cancer Res. , 54 , 152 – 158 ( 1994 ). 7903202 15 ) Lautier , D. , Canitrot , Y. , Deeley , R. G. and Cole , S. P. C. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene . Biochem. Pharmacol. , 52 , 967 – 977 ( 1996 ). 8831715 16 ) Alley , M. C. , Scudiero , D. A. , Monks , A. , Hursey , M. L. , Czwrwinsky , M. J. , Fine , D. L. , Mayo , J. G. , Shoemaker , R. H. and Boyd , M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay . Cancer Res. , 48 , 589 – 601 ( 1988 ). 3335022 17 ) Deffie , A. M. , Batra , J. K. and Goldenberg , G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin‐sensitive and ‐resistant P388 leukemia cell lines . Cancer Res. , 49 , 58 – 62 ( 1989 ). 2535693 18 ) Utsugi , T. , Mattern , M. R. , Mirabelli , C. K. and Hanna , N. Potentiation of topoisomerase inhibitor‐induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation . Cancer Res. , 50 , 2636 – 2640 ( 1990 ). 2158396 19 ) Utsugi , T. , Shibata , J. , Sugimoto , Y. , Aoyagi , K. , Wierzba , K. , Kobunai , T. , Terada , T. , Oh‐hara , T. , Tsuruo , T. and Yamada , Y. Antitumor activity of a novel podophyllotoxin derivative (TOP‐53) against lung cancer and lung metastatic cancer . Cancer Res. , 56 , 2809 – 2814 ( 1996 ). 8665518 20 ) Desjardin , E. L. , Chen , Y. , Perkins , D. M. , Teixeira , L. , Cave , D. M. and Eisenach , D. K. Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis . J. Clin. Microbiol. , 36 , 1964 – 1968 ( 1998 ). 9650945 21 ) Luthra , R. , McBride , J. A. , Cabanillas , F. and Sarris , A. Novel 5′‐exonuclease‐based real‐time PCR assay for detection of t(14;18)(q32;q21) in patients with follicular lymphoma . Am. J. Pathol. , 153 , 63 – 68 ( 1998 ). 9665466 22 ) van der Valk , P. , van der Kalken , C. K. , Ketelaas , H. , Boxterman , H. J. , Scheffer , G. L. , Kuiper , C. M. , Tsuruo , T. , Lankerma , C. J. L. M. , Pinedo , H. M. and Scheper , R. J. Distribution of multidrug resistance‐associated P‐glucoprotein in normal and neoplastic human tissue . Ann. Oncol. , 1 , 56 – 64 ( 1990 ). 1706611 23 ) Scheper , R. J. , Broxterman , H. J. , Scheffer , G. L. , Kaaijk , P. , Dalton , W. S. , van Heijningen , T. H. M. , van Kalken , C. K. , Slovak , M. L. , de Vries , E. G. E. , van der Valk , P. , Meijer , C. J. L. M. and Pinedo , H. M. Overexpression of a Mr 110,000 vesicular protein in non‐P‐glycoprotein‐mediated multidrug resistance . Cancer Res. , 53 , 1475 – 1479 ( 1993 ). 7680954 24 ) Yabuki , N. , Sasano , H. , Kato , T. , Ohara , S. , Toyota , M. , Nagura , H. , Miyaike , A. , Nozaki , N. and Kikuchi , A. Immunohistochemical study of DNA topoisomerase II in human gastric disorder . Am. J. Pathol. , 149 , 997 – 1007 ( 1996 ). 8780403 25 ) Withoff , S. , Vries , E. G. E. , Keith , W. N. , Nienhuis , E. F. , Greef , W. T. A. , Uges , D. R. A. and Mulder , N. H. Differential expression of DNA topoisomerase II α and ‐β on Pgp and MRP‐negative VM26, mAMSA and mitoxantrone resistant sublines of the human SCLC cell line GCL4 . Br. J. Cancer , 74 , 1869 – 1876 ( 1996 ). 8980384 26 ) Hazlehurst , L. A. , Foley , N. E. , Gleason‐Guzman , M. C. , Hacker , M. P. , Cress , A. E. , Greenberger , L. W. , De Jong , W. C. and Dalton , W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line . Cancer Res. , 59 , 1021 – 1028 ( 1999 ). 10070958 27 ) Deruddre , S. , Dalaporte , C. and Jacquemin‐Sablom , A. Role of topoisomerase II β in the resistance of 9‐OH‐ellipticine‐resistant Chinese hamster fibroblast to topoisomerase II inhibitors . Cancer Res. , 57 , 4301 – 4308 ( 1997 ). 9331091 28 ) Austin , C. A. and Marsh , K. L. Eukaryotic DNA topoisomerase IIβ BioEssays , 20 , 215 – 226 ( 1998 ). 9631649 29 ) Woessner , R. D. , Mattern , M. R. , Mirabelli , C. K. , Johnson , R. K. and Drake , F. H. Proliferation‐ and cell cycle‐dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH‐3T3 cells . Cell Growth Differ. , 2 , 209 – 214 ( 1991 ). 1651102 30 ) Prosperi , E. , Marchese , G. and Astaldi‐Ricotti , G. C. B. Expression of the 170‐kDa and 180‐kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes . Cell prolif. , 27 , 257 – 267 ( 1994 ). 10465010 31 ) Turnbull , R. M. , Meczes , E. L. , Perenna Rogers , M. , Lock , R. B. , Sullivan , D. M. , Finlay , G. J. , Bagulay , B. C. and Austin , C. A. Carbamate analogues of amsacrine active against non‐cycling cells: relative activity against topoisomerase II α and β . Cancer Chemother. Pharmacol. , 44 , 275 – 282 ( 1999 ). 10447574 32 ) Baguley , B. C. , Leteurtre , F. , Riou , J. F. , Finlay , G. J. and Pommier , Y. A carbamate analogue of amsacrine with activity against non‐cyclin cells stimulates topoisomerase II cleavage at DNA sites distinct from amsacrine . Eur. J. Cancer , 33 , 272 – 279 ( 1997 ). 9135499 33 ) Tronov , V. A. , Konoplyannikov , M. A. , Nikolskaya , T. A. and Konstantinov , E. A. Apoptosis of unstimulated human lymphocyte and DNA strand breaks induced by the topoisomerase Ii inhibitor etoposide (VP‐16) . Biochemistry , 64 , 345 – 352 ( 1999 ). 10205305 34 ) Young , L. C. , Campling , B. G. , Voskoglou‐Nomikos , T. , Cole , S. P. C. , Deeley , R. G. and Gerlach , J. H. Expression of multidrug resistance protein‐related genes in lung cancer: correlation with drug response . Clin. Cancer Res. , 5 , 673 – 680 ( 1999 ). 10100721 35 ) Lorico , A. , Rappa , G. , Finchi , A. R. , Yang , D. , Flavell , A. R. and Sartorelli , C. A. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP‐16) and increased levels of glutathione . Cancer Res. , 57 , 5238 – 5242 ( 1997 ). 9393741 36 ) Rappa , G. , Lorico , A. , Flavell , A. R. and Sartorelli , C. A. Evidence that the multidrug resistance protein (MRP) functions as a co‐transporter of glutathione and natural product toxins . Cancer Res. , 57 , 5232 – 5237 ( 1997 ). 9393740",
  "plain_text": "6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐ c ]quinol in‐7‐one dihydrochloride (TAS‐103) is a novel anticancer agent that was developed to target both topoisomerase (Topo) I and Topo II. To elucidate its mechanism of action, we have established and characterized TAS‐103‐resistant cells, derived from mouse leukemia (P388), human colon cancer (DLD‐1), and human lung adenocarcinoma (A549) cell lines, by exposure to stepwisely increasing concentrations of TAS‐103 in the culture medium. P388/TAS cells showed only cross‐resistance to VP‐16 and adriamycin (ADR). The Topo II activity in these cells was decreased to below one‐fourth of that in the parental cells, while the Topo I activity remained unchanged. DLD/TAS cells appeared to be cross‐resistant to VP‐16, ADR, camptothecin (CPT), SN‐38 and vincristine (VCR). The enzymatic activities of both Topo I and Topo II in these cells were decreased to one‐fourth of that observed in the parental cells. Furthermore, the decreased activities were accompanied by lower expression at the mRNA and protein levels. A549/TAS cells acquired cross‐resistance to VP‐16, ADR and VCR, though the Topo activities were virtually unchanged. In this cell line, the intracellular accumulation of TAS‐103 was significantly decreased and the expression of multidrug resistance associated protein (MRP) was elevated when compared with the parental cells. The results indicate that the affected activities of Topo I and/or Topo II, and in some instances decreased accumulation of TAS‐103, are associated with the development of resistance to TAS‐103, although the main mechanism of resistance to TAS‐103 varied among cell lines."
}
